Affordable Care Act Marketplace enrollment jumps 18% over last year

The Department of Health and Human Services recently announced that there has been an 18% increase in Affordable Care Act health insurance enrollment over last year’s numbers, in a major victory for the Biden administration’s efforts to expand access to health insurance.  

As of December 15—the Affordable Care Act’s sign-up deadline to receive coverage beginning on January 1, 2023— nearly 11.5 million people had already selected a health care plan through the ACA Health Insurance Marketplace, according to HHS. 

Why the increase? HHS Secretary Xavier Becerra cited increasing affordability, robust competition, and historic outreach efforts as some of the reasons behind the increase, while crediting the Inflation Reduction Act has helped advance efforts on several of these fronts. 

“Thanks to the Inflation Reduction Act, four out of five customers will be able to find a plan for $10 or less. As we head into the new year, there is no greater gift than the peace of mind that comes with having high-quality, affordable health care,” he said. 

Health care impacts brought on by the Inflation Reduction Act include an extension of ACA subsidies, along with other benefits including capping pharmacy costs for Medicare Part D patients to $2,000 and capping insulin costs at $35 per month for all Medicare beneficiaries.  

Overall, the uninsured rate in the U.S. dropped from 10.9% in 2019 to 10.2% in 2021, according to the Kaiser Family Foundation. Numbers for 2020 were not released due to pandemic-related interruptions, and numbers for 2022 are not yet available. 

People looking to enroll in the Affordable Care Act Marketplace can still sign up until January 15, but coverage will not start until February for those who enroll in January.

Jessica Kania is a digital editor who has worked across the Innovate Healthcare brands, including Radiology Business, Health Imaging, AI in Healthcare and Cardiovascular Business. She also has vast experience working on custom content projects focused on technology innovation, clinical excellence, operational efficiency and improving financial performance in healthcare.  

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.